Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

239.36USD
4:00pm EDT
Change (% chg)

$0.68 (+0.28%)
Prev Close
$238.68
Open
$238.42
Day's High
$240.80
Day's Low
$237.51
Volume
1,149,164
Avg. Vol
645,705
52-wk High
$322.66
52-wk Low
$195.51

AGN.N

Chart for AGN.N

About

Allergan plc, formerly Actavis plc, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company's segments are US Brands, US Medical Aesthetics... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $94,505.87
Shares Outstanding(Mil.): 395.95
Dividend: --
Yield (%): --

Financials

  AGN.N Industry Sector
P/E (TTM): -- 36.22 36.20
EPS (TTM): -6.14 -- --
ROI: -1.68 14.42 13.87
ROE: -3.49 15.22 14.78

Pfizer decides against split-up; more deals seen likely

NEW YORK Pfizer Inc , which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines. | Video

12:48pm EDT

UPDATE 4-Pfizer decides against split-up; more deals seen likely

NEW YORK, Sept 26 Pfizer Inc, which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.

Sep 26 2016

Pfizer says not to split into two

Sept 26 U.S. drugmaker Pfizer Inc said on Monday it had decided not to separate into two publicly traded companies at this time.

Sep 26 2016

BRIEF-Allergan gets FDA approval of Natrelle Inspira cohesive breast implants

* Allergan announces FDA approval of natrelle inspira cohesive breast implants Source text for Eikon: Further company coverage:

Sep 23 2016

BRIEF-Allergan and Adamas announce all four dosage strengths of NAMZARIC available throughout U.S.

* Co and Adamas Pharmaceuticals announce all four dosage strengths of NAMZARIC now available by prescription in pharmacies throughout U.S. Source text for Eikon: Further company coverage:

Sep 22 2016

Allergan to buy Tobira in push for fatty liver disease drugs

Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

Sep 20 2016

UPDATE 3-Allergan to buy Tobira in push for fatty liver disease drugs

Sept 20 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

Sep 20 2016

REFILE-DEALTALK-Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Sept 20 Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

Allergan to buy Tobira in push for NASH treatments

Sept 20 Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to $1.7 billion, to gain access to its experimental therapies for a fatty liver disease called NASH.

Sep 20 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.